FDA stiff-arms Aveo on tivo, again; Sunovion Parkinson's drug rejected
→ Aveo Oncology was hit with a fresh setback on Thursday. Its 2013-rejected tivozanib is still not ready for a new marketing application, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
